[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588109":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":12,"locations":18,"responsibleParty":36,"collaborators":7,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":7,"eligibilityCriteria":45,"healthyVolunteers":41,"sex":46,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":7,"studyType":52,"phases":7,"briefSummary":53,"conditions":54,"keywords":7,"overallStatus":21,"whyStopped":7,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"Nanjing First Hospital, Nanjing Medical University","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"PET-CT examination","Intravenous injection of 18F-FAPI-YQ104 for PET-CT examination",[13],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},"Feng Wang","CONTACT","+8602552271491","fengwangcn@hotmail.com",[19],{"facility":20,"status":21,"city":22,"state":23,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"Nanjing First Hospital","RECRUITING","Nanjing","Jiangsu","210001","China","CN",{"type":28,"coordinates":29},"Point",[30,31],118.77778,32.06167,{"lat":31,"lon":30},[34],{"name":35,"role":15,"phone":16,"phoneExt":7,"email":17},"Feng Wang, M.D.",{"type":37,"investigatorFullName":14,"investigatorTitle":38,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Chief physician","100588109","18f-labeled-fap-targeted-molecular-probe-in-early-tumor-diagnosis-100588109",false,"NCT06937112","18F Labeled FAP Targeted Molecular Probe in Early Tumor Diagnosis","Clinical Application of a Novel 18F Labeled Fibroblast Activation Protein (FAP) Targeted Molecular Probe in Early Tumor Diagnosis","Inclusion Criteria:\n\n\\- 1. Volunteer for the trial, with the patient or their legal guardian signing the informed consent form; 2. Volunteers are not limited by gender, and the age range is from 18 to 75 years old, including both ends; 3. Other imaging examination methods (CT, MRI, etc.) revealed tumor occupying lesions; 4. Patients with lung cancer, thyroid cancer, pancreatic cancer, melanoma, and neuroendocrine tumors who can obtain the final pathological results.\n\n5\\. Kidney: GFR \\> 50 ml\u002Fmin, ERPF \\> 280 ml\u002Fmin, platelet count (PLT) \\> 75,000\u002FμL, white blood cell (WBC) \\> 3,000\u002FμL, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels less than 3 times the normal value.\n\nExclusion Criteria:\n\n* 1\\. Individuals with a history of allergies to similar drugs (drugs with similar chemical or biological components to FAPI), allergic constitution, or current allergic diseases; 2. Those who are currently conducting clinical research on other drugs or have participated in any clinical research on drugs (excluding vitamins and minerals); 3. There are other clinical problems that are difficult to control (such as HIV, hepatitis C virus infection or active hepatitis B, or other serious chronic infections and serious mental, neurological, cardiovascular, respiratory and other system diseases); 4. Red blood cell RBC\\\u003C4 × 1012, white blood cell WBC\\\u003C3 × 109, hemoglobin\\\u003C110g\u002FL, PLT\\\u003C75000×109； 5. Significant abnormalities in liver and kidney function, with GFR less than 50 ml\u002Fmin; 6. Tumor burden greater than 50%, or significant spinal cord compression; 7. Expected survival period is less than six months; Chemotherapy within June; 8. Having severe acute comorbidities or severe refractory mental disorders; 9. Pregnant and lactating women (where pregnancy is defined as a positive urine pregnancy study); 10. Patients whose physical condition is not suitable for radiation examination; 11. Other situations that researchers consider unsuitable for participating in the experiment.","ALL","18 Years","75 Years",{"count":50,"type":51},20,"ESTIMATED","OBSERVATIONAL","Evaluate the safety of the novel FAP targeted molecular probe 18F-FAPI-YQ104 labeled with radioactive isotopes in clinical applications and verify its effectiveness in tumor diagnosis.",[55,56,57,58],"Lung Cancers","Pancreatic Cancer","Neuroendocrine Tumors","Thyroid Cancer","2025-04-18",{"date":61,"type":62},"2025-04-22","ACTUAL",{"date":64,"type":62},"2025-04-10",{"date":66,"type":51},"2026-03-31",{"name":5,"class":6},1]